A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
研究单位：[1]Jiangsu HengRui Medicine Co., Ltd.[2]Peking Union Medical College Hospital[3]Anhui Provincial Hospital,Hefei,Anhui,China,230001[4]Beijing Cancer Hospital,Beijing,Beijing,China[5]Beijing Cancer Hospital,Beijing,Beijing,China[6]Chinese PLA General Hospital,Beijing,Beijing,China[7]Peking Union Medical College Hospital,Beijing,Beijing,China[8]The First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China[9]Guangdong Provincial People's Hospital,Guangzhou,Guangdong,China[10]Sun Yat-Sen Memorial Hospital,Guangzhou,Guangdong,China[11]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China[12]The 3rd Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,China[13]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[14]Hubei Cancer Hospital,Wuhan,Hubei,China[15]Jiangsu Cancer Hospital,Nanjing,Jiangsu,China,210009[16]Nanjing Drum Tower Hospital,Nanjing,Jiangsu,China[17]Shandong Cancer Hospital and Institute,Jinan,Shandon,China[18]Changhai Hospital,Shanghai,Shanghai,China[19]Fudan University Shanghai Cancer Center,Shanghai,Shanghai,China[20]Huashan Hospital, Fudan University,Shanghai,Shanghai,China[21]Ruijin Hospital, Shanghai Jiaotong University School of Medicine,Shanghai,Shanghai,China[22]Xinhua Hospital Affilited to Shanghai Jiao Tong University School of Medicine,Shanghai,Shanghai,China[23]Sichuan Cancer Hospital Institute,Chengdu,Sichuan,China[24]West China Hospital,Chengdu,Sichuan,China[25]Tianjin Medical University Cancer Institute & Hospital,Tianjin,Tianjin,China[26]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,Zhejiang,China
研究目的：
The study is being conducted to evaluate the tolerability, safety and efficacy of maintenance Fluzoparib monotherapy in patients with gBRCA/PALB2 mutated metastatic pancreatic cancer whose disease has not progressed on first line platinum based chemotherapy.
